Recursion founder Chris Gibson to leave board, stay as advisor through June 2026

Recursion Pharmaceuticals announced that Chris Gibson, Ph.D., founder and current board member, will complete his term through June 2026 but will not seek re-election. Gibson will continue supporting the company as a strategic advisor. The company emphasized its focus on leadership continuity and advancing its AI-driven drug discovery platform to deliver new therapies. CEO Najat Khan expressed optimism about the company's future under current leadership and ongoing pipeline progress.